Dr. Call is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1989 - 1993
- Gundersen Lutheran Medical FoundationResidency, Internal Medicine, 1980 - 1983
- University of Wisconsin School of Medicine & Public HealthClass of 1980
Certifications & Licensure
- MN State Medical License 1990 - 2025
- WI State Medical License 1981 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia Start of enrollment: 2000 Feb 01
- Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Start of enrollment: 2013 Apr 30
Publications & Presentations
PubMed
- Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.Paul J Hampel, Kari G Rabe, Yucai Wang, Steven R Hwang, Saad S Kenderian
Leukemia. 2024-12-10 - Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism.Amber B Koehler, Kari G Rabe, Daniel J Crusan, Timothy G Call, Sara J Achenbach
Journal of Thrombosis and Haemostasis. 2024-09-27 - 3 citationsHairy cell leukemia variant and WHO classification correspondence Re: 5edition WHO classification haematolymphoid tumors: lymphoid neoplasms.Michael Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji
Leukemia. 2024-07-01
Journal Articles
- Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical CentreSameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology
Abstracts/Posters
- A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...Timothy G. Call, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphoc...Timothy G. Call, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of ProgressionTimothy G. Call, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Newer CLL Agents Require Specific Management TechniquesJune 27th, 2017
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: